← All calls
biotechResolvedNO DIRECTION

FDA decision (PDUFA) — RARE DTX401 gene therapy

Will the FDA approve DTX401 gene therapy (RARE) on/around 2026-08-23? glycogen storage disease Ia

premise not yet verified
EHIQ graded opening
50%
Market
—
gap vs market
—
—

Thesis

AUTO-SOURCED from the FDA catalyst calendar. NEEDS CALIBRATION before it goes to subscribers: set the EHIQ probability from endpoint quality (hard vs surrogate), trial design (RCT vs single-arm), and any prior CRL, then set digest_excluded=false. Placeholder prob 0.50 = max uncertainty.

Resolution

Outcome
YES
Resolved
September 1, 2026

[2026-10-16 eric-stamp KN] Labelled no-direction: EHIQ's graded at-open probability was exactly 0.50, which has no direction, so this call is neither a hit nor a miss. The stored hit column, actual_outcome and every probability are unchanged; ties stay in the hit-rate denominator (SCORING_POLICY §5). [2026-10-18 eric-stamp QAU-D4] Outcome recorded: YES. Ultragenyx 8-K, Item 8.01, filed 2026-08-19 (https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/rare-20260819.htm): "the U.S. Food and Drug Administration (the “FDA”) granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401". Approved 2026-08-19, four days before the 2026-08-23 PDUFA date. EHIQ was 50% at open, so the verdict stays NO DIRECTION (neither a hit nor a miss); recording the outcome adds the row to Brier at 0.25. hit, resolution, resolved_at and every probability are unchanged.

Opened
July 18, 2026
Expected resolution
August 23, 2026

Get an alert the moment this call resolves.

Each published EHIQ call carries a resolution date; when it resolves, the verdict is posted here. Subscribe free and we email you when this one grades, plus the weekly divergence leaderboard.

Free forever. Unsubscribe anytime. No spam.